Loading live market data…

Bruker Corporation

NASDAQ:BRKR

$59.83 USD

$0.86 (1.46%)

Volume
1.47M
Average Volume
2.51M
Market Capitalization
$9.11B
P/E Ratio
-250.33
Dividend Yield
0.33%
Price Target
$51.50
Year High
$64.54
Year Low
$28.53
Day High
Day Low
Payout Ratio
$-3.78
Current Ratio
$1.55
Source Headline
Bruker Gains 50.3% in a Year: What's Driving the Rally?

BRKR's rally is fueled by BSI NANO growth, AI-driven metrology demand and gains in preclinical imaging despite tariff pressures.

zacks.com - 2026-06-19 09:36:04

The Healthcare M&A Wave

In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

forbes.com - 2026-06-17 12:30:08

Bruker Corp (BRKR) Stock Up 4.4% and Still Undervalued -- GF Score: 85/100

On June 15, 2026, Bruker Corp (BRKR) shares rose 4.4% to a current price of $56.63. The stock has shown remarkable performance within the past year, with a 48.7

gurufocus.com - 2026-06-15 20:28:00

Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-08 09:58:30

Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam

Bruker NASDAQ: BRKR is seeing stronger order momentum across several end markets, with semiconductor metrology, non-U.S. academic and government customers, and parts of its diagnostics business helping offset continued weakness in U.S. academic funding, a company representative said at a Jefferies healthcare conference.

marketbeat.com - 2026-06-06 18:40:50

Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?

Bruker (BRKR) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-05 12:36:14

State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?

Explore how these two healthcare ETFs differ in diversification, sector focus, and portfolio concentration-key factors shaping their long-term investor appeal.

fool.com - 2026-06-04 13:13:26

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

WASHINGTON--(BUSINESS WIRE)---- $BRKR #BRKR--At ASM Microbe 2026, Bruker Corporation's (Nasdaq: BRKR) Microbiology & Infection Diagnostics (BMID) division is demonstrating its expanding portfolio and innovations across microbial identification, sepsis diagnostics, molecular testing, and NGS workflows, advancing clinical research, and faster, actionable infectious disease diagnostics. During the ASM 2026 meeting, Bruker showcases the expanded clinical capabilities of the MALDI Biotyper® CA System enabled by.

businesswire.com - 2026-06-04 07:00:00

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

At ASMS, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, susta

gurufocus.com - 2026-06-02 12:00:00

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the new timsMRMS system, designed to empower researchers in petroleomics, sustainable fuels and advanced energy storage. The timsMRMS is an innovative platform that combines Trapped Ion Mobility Spectrometry (TIMS) with extreme-resolution Magnetic Resonance Mass Spectrometry (MRMS), to unravel the complex molecular makeup of challenging fossil fuels and green energy materials. It accomplishes this wit.

businesswire.com - 2026-06-02 11:24:00

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics -- all to Enabl

At ASMS, [url="]Bruker Corporation[/url] (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separati

gurufocus.com - 2026-06-01 08:00:00

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--At ASMS, Bruker Corporation (Nasdaq: BRKR) announced the launch of the unique timsMRMS system, bringing the power of trapped ion mobility separation to ultra-high-resolution magnetic resonance mass spectrometry (MRMS). A translational oncology research initiative by Prof. Stephan Singer at University Hospital Tübingen enables therapy selection, measuring more than 10,000 proteins in FFPE biopsies to reveal actionable tumor biology when precision genomics is inconclus.

businesswire.com - 2026-06-01 07:00:00

Champalimaud Foundation's Neuroscience and Oncology Research Benefits from 18 Tesla Ultra-High Field MRI

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation announced the commissioning of a novel BioSpec™ 18 Tesla preclinical MRI, the world's highest-field horizontal-bore MRI system, at the Champalimaud Foundation in Lisbon, Portugal. The BioSpec 18T system provides increased spatial resolution and sensitivity, enabling advanced magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) methods for cancer and neuroscience research, where characterization of tissue micro.

businesswire.com - 2026-05-26 07:00:00

BRKR Stock Up Post Q1 Earnings & Revenue Beat, Margins Down

Bruker beats Q1 earnings and revenue estimates as Europe growth and strong BSI bookings offset margin pressure and softer organic sales.

zacks.com - 2026-05-07 11:30:37

Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript

Bruker Corporation (BRKR) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 23:11:16

Bruker (BRKR) Surpasses Q1 Earnings and Revenue Estimates

Bruker (BRKR) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.47 per share a year ago.

zacks.com - 2026-05-06 08:45:43

Bruker Reports First Quarter 2026 Financial Results

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three months ended March 31, 2026. Frank H. Laukien, Bruker's President and CEO, commented: “While US academic demand, tariff and currency headwinds still pressured our first quarter results, our Q1 financial performance came in ahead of expectations. We are encouraged that our first quarter BSI segment bookings grew organically at a high single digit percentage, and our BSI book-to-bi.

businesswire.com - 2026-05-06 06:30:00

Bruker Corp (BRKR) Shares Fall 5.4% -- What GF Score of 81 Tells Investors

On April 29, 2026, Bruker Corp (BRKR) shares fell 5.4% to $34.29, continuing a downward trend that has seen a 27.1% decline year-to-date. The stock has traded w

gurufocus.com - 2026-04-29 18:03:00

Forget Neuralink: The Real Brain Tech Trade Has 10 Names You’ve Never Heard

The real brain computer interface opportunity isn't in the headlines. These 10 stocks are building the systems that make it possible.

investorplace.com - 2026-04-25 00:00:00

Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report first quarter 2026 financial results before market opening on Wednesday, May 6, 2026. The Company will host a conference call and webcast at 8:00 a.m. Eastern Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presenta.

businesswire.com - 2026-04-24 07:00:00

A Look at Bruker Corp (BRKR) After 4.5% Gain -- GF Value $71.47 vs Price $40.70

On April 17, 2026, Bruker Corp (BRKR) shares rose 4.5% today, bringing the current price to $40.70. The stock has experienced a 52-week range of $28.53 to $56.2

gurufocus.com - 2026-04-17 19:01:00

Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026

SAN DIEGO--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced new updates from Bruker Spatial Biology to be showcased at the 2026 American Association for Cancer Research (AACR) Annual Meeting. At AACR, Bruker Spatial Biology will highlight how its high-fidelity spatial platforms—designed to work together—deliver deeper insights into oncology biology and accelerate translational research. At AACR 2026, Bruker Spatial Biology will launch new cross‑platform workflows linking GeoMx.

businesswire.com - 2026-04-17 09:00:00

Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026

MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, the Bruker Microbiology & Infection Diagnostics division (Bruker Corporation, Nasdaq: BRKR) announces the European launch of MyGenius PRO®, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology. Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operati.

businesswire.com - 2026-04-17 06:00:00

Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management

MUNICH--(BUSINESS WIRE)---- $BRKR #BRKR--At ESCMID Global 2026, Bruker announces important portfolio enhancements across microbial identification, outbreak analysis, and reflex next‑generation sequencing (NGS) typing. These latest developments underscore Bruker's continued commitment to advancing integrated, high‑performance solutions that support laboratories in addressing evolving infectious disease challenges. MALDI Biotyper® Workflow and Identification Enhancements To further streamline routine MALDI‑TOF w.

businesswire.com - 2026-04-17 06:00:00

Get BRKR Insider Trade Alerts

BRKR Price Target Summary

Last Month

$65.00

2 analysts

Last Quarter

$54.60

5 analysts

Last Year

$50.41

22 analysts

All Time

$54.67

27 analysts

BRKR Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-08 Citigroup Maintain Neutral Neutral
2026-07-07 Leerink Partners Maintain Outperform Outperform
2026-06-29 Guggenheim Maintain Buy Buy
2026-06-24 Barclays Maintain Overweight Overweight
2026-06-08 JP Morgan Maintain Overweight Overweight
2026-05-07 Barclays Maintain Overweight Overweight
2026-05-07 TD Cowen Maintain Hold Hold
2026-05-07 Citigroup Maintain Neutral Neutral
2026-05-07 UBS Maintain Neutral Neutral
2026-04-15 Barclays Maintain Overweight Overweight
2026-04-14 Barclays Maintain Overweight Overweight
2026-03-30 Guggenheim Maintain Buy Buy
2026-02-13 Barclays Maintain Overweight Overweight
2026-02-13 Goldman Sachs Maintain Sell Sell
2026-02-13 TD Cowen Maintain Hold Hold
2026-02-13 Citigroup Maintain Neutral Neutral
2026-01-26 Guggenheim Maintain Buy Buy
2026-01-16 Citigroup Maintain Neutral Neutral
2026-01-07 TD Cowen Maintain Hold Hold
2026-01-05 Guggenheim Maintain Buy Buy
2025-12-15 Barclays Maintain Overweight Overweight
2025-12-15 B of A Securities Maintain Buy Buy
2025-12-15 Wells Fargo Maintain Overweight Overweight
2025-12-15 JP Morgan Maintain Overweight Overweight
2025-12-10 Wolfe Research Upgrade Peer Perform Outperform
2025-11-05 Wells Fargo Maintain Overweight Overweight
2025-11-04 TD Cowen Maintain Hold Hold
2025-11-04 Barclays Maintain Overweight Overweight
2025-11-04 UBS Maintain Neutral Neutral
2025-10-02 Barclays Maintain Overweight Overweight
2025-08-05 Stifel Maintain Hold Hold
2025-08-05 Wells Fargo Maintain Overweight Overweight
2025-08-04 Barclays Maintain Overweight Overweight
2025-08-04 Jefferies Maintain Buy Buy
2025-08-04 Citigroup Maintain Neutral Neutral
2025-06-26 B of A Securities Maintain Buy Buy
2025-05-22 Citigroup Downgrade Buy Neutral
2025-05-08 Barclays Maintain Overweight Overweight
2025-05-08 UBS Maintain Neutral Neutral
2025-05-08 Goldman Sachs Maintain Neutral Neutral
2025-05-08 Stifel Maintain Hold Hold
2025-04-17 Wells Fargo Maintain Overweight Overweight
2025-04-10 Barclays Maintain Overweight Overweight
2025-04-07 Citigroup Maintain Buy Buy
2025-02-24 Guggenheim Maintain Buy Buy
2025-02-14 Stifel Maintain Hold Hold
2025-02-14 Barclays Maintain Overweight Overweight
2025-02-10 Barclays Maintain Overweight Overweight
2025-01-17 Guggenheim Maintain Buy Buy
2024-12-13 B of A Securities Maintain Buy Buy
2024-12-05 Goldman Sachs Upgrade Sell Neutral
2024-11-06 TD Cowen Maintain Hold Hold
2024-11-06 Barclays Maintain Overweight Overweight
2024-11-06 Wells Fargo Maintain Overweight Overweight
2024-11-06 Citigroup Maintain Buy Buy
2024-09-30 Wolfe Research Downgrade Outperform Peer Perform
2024-08-07 TD Cowen Maintain Hold Hold
2024-07-10 Citigroup Maintain Buy Buy
2024-07-09 Goldman Sachs Maintain Sell Sell
2024-05-20 Stifel Maintain Hold Hold
2024-05-20 B of A Securities Maintain Buy Buy
2024-04-10 Goldman Sachs Maintain Sell Sell
2024-03-01 UBS Maintain Buy Buy
2024-02-15 UBS Maintain Buy Buy
2024-02-14 Citigroup Maintain Buy Buy
2024-02-14 JP Morgan Upgrade Neutral Overweight
2024-02-14 Stifel Maintain Hold Hold
2023-10-17 JP Morgan Maintain Neutral Neutral
2023-05-05 Citigroup Maintain Buy Buy
2023-04-19 Goldman Sachs Maintain Sell Sell
2023-04-18 Goldman Sachs Maintain Sell Sell
2023-02-10 Citigroup Maintain Buy Buy
2022-10-21 UBS Maintain Buy Buy
2022-08-22 Citigroup Upgrade Neutral Buy
2022-05-05 SVB Leerink Maintain Outperform Outperform
2022-04-13 Goldman Sachs Maintain Sell Sell
2022-02-14 SVB Leerink Maintain Outperform Outperform
2021-11-02 Wells Fargo Maintain Equal Weight Equal Weight
2021-09-09 SVB Leerink Maintain Outperform Outperform
2021-08-03 Wells Fargo Maintain Equal Weight Equal Weight
2021-06-18 SVB Leerink Maintain Outperform Outperform
2021-06-15 Cleveland Research Upgrade Neutral Buy
2021-02-05 Wells Fargo Downgrade Overweight Equal Weight
2021-01-27 SVB Leerink Maintain Outperform Outperform
2020-11-16 Wolfe Research Upgrade Underperform Peer Perform
2020-08-04 Citigroup Maintain Neutral Neutral
2020-08-04 SVB Leerink Maintain Outperform Outperform
2020-07-20 B of A Securities Maintain Buy Buy
2020-05-07 Citigroup Maintain Neutral Neutral
2020-05-07 Wells Fargo Maintain Overweight Overweight
2020-04-28 UBS Maintain Neutral Neutral
2020-04-02 Stifel Maintain Hold Hold
2020-04-01 Needham Downgrade Strong Buy Hold
2020-03-26 Barclays Upgrade Equal Weight Overweight
2020-03-20 Citigroup Maintain Neutral Neutral
2020-02-19 Needham Maintain Strong Buy Strong Buy
2020-01-08 Wells Fargo Maintain Overweight Overweight
2020-01-07 Citigroup Maintain Buy Buy
2019-11-15 Stifel Nicolaus Maintain Hold Hold
2019-09-26 B of A Securities Upgrade Neutral Buy
2019-09-26 Bank of America Upgrade Neutral Buy
2019-07-15 Goldman Sachs Upgrade Sell Neutral
2019-05-03 SVB Leerink Upgrade Market Perform Outperform
2019-04-12 Deutsche Bank Maintain Buy Buy
2019-01-03 Needham Downgrade Strong Buy Buy
2018-09-20 Morgan Stanley Downgrade Equal Weight Underweight
2018-08-03 Morgan Stanley Maintain Equal Weight Equal Weight
2018-07-13 Morgan Stanley Maintain Equal Weight Equal Weight
2018-05-04 Bank of America Maintain Neutral Neutral
2018-05-04 B of A Securities Maintain Neutral Neutral
2018-04-11 Morgan Stanley Maintain Equal Weight Equal Weight
2018-02-09 Leerink Swann Maintain Market Perform Market Perform
2018-02-09 Morgan Stanley Maintain Equal Weight Equal Weight
2018-01-05 BTIG Research Maintain Buy Buy
2018-01-04 Evercore ISI Group Maintain In Line In Line
2017-12-19 Morgan Stanley Maintain Equal Weight Equal Weight
2017-12-14 Morgan Stanley Maintain Equal Weight Equal Weight
2017-11-05 JP Morgan Upgrade Underweight Neutral
2017-11-03 B of A Securities Upgrade Underperform Neutral
2017-11-03 JP Morgan Upgrade Underweight Neutral
2017-11-03 Bank of America Upgrade Underperform Neutral
2017-11-03 Citigroup Maintain Neutral Neutral
2017-07-13 Wells Fargo Downgrade Market Perform Underperform
2017-01-18 Deutsche Bank Maintain Hold Hold
2017-01-04 Barclays Downgrade Overweight Equal Weight
2016-12-14 JP Morgan Downgrade Neutral Underweight
2016-08-03 Wells Fargo Downgrade Outperform Market Perform
2016-08-03 Janney Montgomery Scott Upgrade Neutral Buy
2016-08-03 Janney Capital Upgrade Neutral Buy
2016-08-03 Barclays Maintain Overweight Overweight
2016-05-05 BTIG Downgrade Buy Neutral
2016-05-05 BTIG Research Downgrade Buy Neutral
2016-05-05 Leerink Swann Maintain Market Perform Market Perform
2016-04-05 B of A Securities Downgrade Neutral Underperform
2016-04-05 Leerink Swann Downgrade Outperform Market Perform
2016-04-05 Bank of America Downgrade Neutral Underperform
2016-03-01 Barclays Maintain Overweight Overweight
2016-02-11 Deutsche Bank Maintain Hold Hold
2016-01-25 Cantor Fitzgerald Upgrade Hold Buy
2016-01-06 Avondale Partners Maintain Market Perform Perform
2016-01-06 Deutsche Bank Maintain Hold Hold
2015-11-12 Stifel Nicolaus Maintain Buy Buy
2015-11-05 Leerink Swann Maintain Outperform Outperform
2015-09-15 Morgan Stanley Maintain Equal Weight Equal Weight
2015-08-27 Cantor Fitzgerald Maintain Hold Hold
2015-05-21 Mizuho Downgrade Buy Neutral
2015-05-21 William Blair Downgrade Outperform Market Perform
2015-04-06 Leerink Swann Upgrade Market Perform Outperform
2015-03-10 UBS Maintain Neutral Neutral
2015-02-20 JP Morgan Maintain Neutral Neutral
2015-02-19 Jefferies Maintain Buy Buy
2015-02-19 Citigroup Maintain Neutral Neutral
2015-02-10 B of A Securities Downgrade Buy Neutral
2015-02-10 Bank of America Downgrade Buy Neutral
2015-01-09 Cowen & Co. Downgrade Outperform Market Perform
2014-12-18 Goldman Sachs Downgrade Buy Sell
2014-11-07 Cantor Fitzgerald Downgrade Buy Hold
2014-11-07 B of A Securities Maintain Buy Buy
2014-11-07 Citigroup Maintain Neutral Neutral
2014-11-07 Bank of America Maintain Buy Buy
2014-08-07 Citigroup Maintain Buy Buy
2014-07-08 ISI Group Downgrade Buy Neutral
2014-06-19 Wells Fargo Upgrade Market Perform Outperform
2013-11-06 Morgan Stanley Maintain Overweight Overweight
2013-09-27 Maxim Group Maintain Buy Buy
2013-09-20 Wells Fargo Downgrade Outperform Market Perform
2013-09-20 Cleveland Research Maintain Buy Buy
2013-08-15 Janney Capital Maintain Neutral Neutral
2013-08-09 Bank of America Upgrade Neutral Buy
2013-08-09 B of A Securities Upgrade Neutral Buy
2013-08-01 Jefferies Maintain Buy Buy
2013-07-22 Cowen & Co. Maintain Outperform Outperform
2013-05-03 Mizuho Upgrade Neutral Buy
2013-03-21 Jefferies Upgrade Hold Buy
2013-02-21 Bank of America Upgrade Underperform Neutral
2013-02-21 B of A Securities Upgrade Underperform Neutral
2013-02-20 UBS Maintain Buy Buy
2013-02-19 JP Morgan Maintain Neutral Neutral
2013-01-31 UBS Maintain Buy Buy
2013-01-07 ISI Group Upgrade Neutral Buy
2012-11-19 Goldman Sachs Upgrade Neutral Buy
2012-11-06 UBS Maintain Buy Buy
2012-11-05 ISI Group Maintain Market Weight Market Weight
2012-08-21 ISI Group Maintain Market Weight Market Weight
2012-08-01 UBS Maintain Buy Buy
2012-07-31 Cantor Fitzgerald Maintain Buy Buy
2012-07-24 B of A Securities Maintain Underperform Underperform
2012-07-24 Bank of America Maintain Underperform Underperform
2012-07-24 Jefferies Maintain Hold Hold
2012-07-12 Cantor Fitzgerald Maintain Buy Buy
2012-07-11 JP Morgan Downgrade Overweight Neutral
2012-07-10 ISI Group Maintain Market Weight Equal Weight
2012-05-02 UBS Maintain Buy Buy
2012-05-02 Jefferies Maintain Hold Hold
2012-02-22 Jefferies Maintain Hold Hold